<DOC>
	<DOCNO>NCT02833883</DOCNO>
	<brief_summary>The main purpose study define good and/or bad effect combination enzalutamide CC-115 patient castration-resistant prostate cancer .</brief_summary>
	<brief_title>Use Experimental Drug , CC-115 , With Enzalutamide Men With Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Willing able provide write informed consent HIPAA authorization release personal health information . NOTE : HIPAA authorization may either include informed consent obtain separately . Males 18 year age life expectancy least 6 month . Histological cytological proof prostate cancer Willing provide tumor sample via biopsy metastatic site disease collect screen safe feasible per treat investigator discretion . Adequate archival metastatic tissue use available lieu baseline biopsy do patient CRPC . Documented progressive metastatic CRPC base least one follow criterion : Rise PSA : minimum 3 rising level , interval least 1 week determination . The last determination must value ≥1 ng/mL , obtain within 4 week start study drug Measurable disease : new progressive soft tissue disease computerize tomography ( CT ) magnetic resonance image Radionuclide bone scan : least 2 new bone lesion , define Prostate Cancer Clinical Trials Working Group 2 ( PCWG2 ) criteria33 Serum testosterone &lt; 50 ng/dL . Patients must continue primary androgen deprivation LHRH analogue ( agonist antagonist ) undergone orchiectomy ECOG performance status 01 Finasteride , bicalutamide nilutamide discontinue least 4 week prior registration . Physiologic dose corticosteroid permit ( i.e. , 10mg prednisone daily ) . At least 4 week must elapse use palliative radiation , Strontium89 , Radium223 , approve immunotherapy prior registration . Less equal 5 half live 4 week , whichever short , use investigational therapy prior registration . Normal organ function acceptable initial laboratory value within 14 day registration . ANC ≥ 1,500/μl Hemoglobin ≥ 9g/dL Platelet count ≥ 100,000/μl Creatinine ≤ 1.5 x institutional upper limit normal ( ULN ) , 24hr clearance ≥50 mL/min Potassium ≥ 3.5 mmol/L ( within institutional normal range , correctable supplement ) Bilirubin ≤ 1.5 x ULN ( unless document Gilbert 's disease ) SGOT ( AST ) ≤ 2.5 x ULN SGPT ( ALT ) ≤ 2.5 x ULN Glycated hemoglobin ( HbA1c &lt; 6.4 % Able take oral medication without crush , dissolve chew tablet . Able adhere study visit schedule protocol requirement . Prior exposure enzalutamide , ARN509 , investigational ARdirected therapy Prior exposure abiraterone acetate , ketoconazole specific CYP17 inhibitor Prior exposure agent specifically target mTOR complex ( dual TORC1+TORC2 inhibitor ) and/or PI3K/AKT pathway Prior chemotherapy castration resistant disease . Chemotherapy give castrationsensitive setting permissible . At least 6 month registration must elapse since chemotherapy last receive . Symptomatic central nervous system metastasis Known history acute chronic pancreatitis Persistent diarrhea malabsorption ≥ NCI CTCAE Grade 2 , despite medical management Clinically significant cardiac disease , include follow : Unstable angina pectoris Myocardial infarction ≤ 3 month prior registration Other clinically significant heart disease congestive heart failure require treatment uncontrolled hypertension Uncontrolled diabetes mellitus Other concurrent severe and/or uncontrolled concomitant medical condition ( e.g. , active uncontrolled infection ) could cause unacceptable safety risk compromise compliance protocol Major surgery ≤ 2 week prior registration recover side effect therapy . Subjects must recover effect recent radiotherapy might confound safety evaluation study drug . Hematopoietic stem cell transplant ≤ 3 month prior registration . Adults reproductive potential employ two form birth control : Males partner female childbearing potential must agree and/or partner use least two effective contraceptive method ( include one barrier method ) engage reproductive sexual activity throughout study time inform consent , avoid conceive 28 day last dose CC115 . Known human immunodeficiency virus ( HIV ) infection Known chronic hepatitis B C virus ( HBV/HCV ) infection Concurrent active second malignancy subject receive therapy , nonmelanomatous skin cancer superficial transitional cell carcinoma . History seizure condition may predispose seizure include , limited , underlie brain injury , stroke past 6 month , primary brain tumor , brain metastasis Active treatment medication low seizure threshold hold : Aminophylline/theophylline ; Atypical antipsychotic ( e.g. , clozapine , olanzapine , risperidone , ziprasidone ) ; Bupropion ; Lithium ; Pethidine ; Phenothiazine antipsychotic ( e.g. , chlorpromazine , mesoridazine , thioridazine ) ; Tricyclic tetracyclic antidepressant ( e.g. , amitriptyline , desipramine , doxepin , imipramine , maprotiline , mirtazapine ) . Any condition , opinion Investigator , would preclude participation trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Enzalutamide</keyword>
	<keyword>CC-115</keyword>
	<keyword>16-074</keyword>
</DOC>